At the Department of Abdominal Oncology at the National Cancer Institute of Naples in Italy, an expert pharmacist was involved in evaluating the economic impact of improving the Italian registry of high-cost drugs, particularly bevacizumab, cetuximab, panitumumab, and trastuzumab.
Worldwide, biologic drugs in the oncology setting represent a rapidly growing expense. In recent years, many European healthcare systems have entered into Managed Entry Agreements (MEAs) to facilitate access to high-cost biologics. These agreements may consist of price-volume discounts or dose-capping agreements with drug makers, or they may consist of outcomes-based contracts.
A paper recently published in Frontiers in Public Health describes the practice experience of the Department of Abdominal Oncology at the National Cancer Institute of Naples in Italy. In this center, an expert pharmacist was involved in evaluating the economic impact of improving the Italian registry of high-cost drugs, particularly bevacizumab, cetuximab, panitumumab, and trastuzumab.
Working together with clinicians from 2016 to 2017, the pharmacist was involved in collecting patient data, evaluating eligibility criteria, tracking the drugs dispensed, monitoring disease status, reporting adverse events, and providing follow-up. The pharmacist also managed reimbursement requests with drug companies.
During 2016, 473 patients were treated with bevacizumab (versus 373 patients in 2015), 175 were treated with cetuximab (versus 169 in 2015), 139 were treated with panitumumab (versus 86 in 2015), and 45 were treated with trastuzumab (versus 36 in 2015). Reimbursement grew to the equivalent of approximately $1 million in 2016 versus approximately $245,052 in 2015, an increase not attributable to the relatively modest growth in the number of patients treated.
In fact, the authors report, most of the reimbursement increase was attributable to MEA activity for bevacizumab, and the increase was directly linked to more careful monitoring and more timely submission of requests for reimbursement to pharmaceutical companies through the MEAs.
The experience of this center, say the authors, “can be considered as an exploratory report lacking in literature data on the integration of Pharmacists into the clinical multidisciplinary teams. Improving the management of MEA-related issues could represent a successful strategy in the ‘real world’ to improve reimbursements and finally reduce the costs of biologic drugs.”
Reference
Capozzi M, De Divitiis C, Ottaiano A, et al. Funds reimbursement of high-cost drugs in gastrointestinal oncology: an Italian real practice 1 year experience at the National Cancer Institute of Naples. Front Public Health. 2018;6:291. doi: 10.3389/fpubh.2018.00291.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).